David Weinberg, MD
Gastroenterology · Philadelphia, PANPI 1023088317
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,150 of the $48,491 with a category attached, or 99.3%. Merck accounts for 99.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $10,725 and has fallen 99.6% since, to $43 in 2025. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $2309.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$48K
- Boston Scientific$179
- Fujifilm Healthcare Americas Corporation$67
- AstraZeneca$43
- Merge Healthcare Incorporated$25
- Chiesi USA, Inc.$14
- plus $11 from 1 others
Across 24 payments — averaging $3706.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$89K
What the payments were for
- Consulting fees$48,15099%
- Food & beverage$2971%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $48,150 |
| Boston Scientific | 6 | $179 |
| Fujifilm Healthcare Americas Corporation | 1 | $67 |
| AstraZeneca | 1 | $43 |
| Merge Healthcare Incorporated | 2 | $25 |
| Chiesi USA, Inc. | 1 | $14 |
| Concordia Pharmaceuticals Inc. | 1 | $11 |
How this compares
$48,491 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 24 | $12,296 |
| Entecavir | 12 | $8,400 |
| Mesalamine ErMesalamine | 15 | $3,938 |
| Esomeprazole Magnesium | 23 | $471 |
| Omeprazole | 59 | $458 |
| Pantoprazole Sodium | 79 | $457 |
| Famotidine | 14 | $135 |
| Metoclopramide Hcl | 18 | $50 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Philadelphia
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Gregory GinsbergPhiladelphia$234K
- Neilanjan NandiPhiladelphia$209K
- David LichtensteinPhiladelphia$192K
- Alexander SchlachtermanPhiladelphia$188K
- Kuchikala ReddyPhiladelphia$182K
- James LewisPhiladelphia$175K
- Beth GardnerPhiladelphia$122K
- Gary FalkPhiladelphia$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.